This very significant development could become the standard treatment for prostate cancer in the future.
Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer. NIH Study- Recruiting- ClinicalTrials.gov Identifier: NCT01875250
You must log in to post a comment.